Donald Smith authored a white paper that defines the Pre-Approval Information Exchange (PIE) Act, compares it to the U.S. Food and Drug Administration (FDA) guidance, and outlines how implementation will support advancement of new therapies to market.
📥 https://t.co/kA4mItnA3C
Standing room only! 👏
Paulina Rolska-Wójcik and Jessica Griffiths, members of our value and access consulting team, presented a HEOR Theater session on the new EU HTA regulation in front of an overflow crowd at #ISPOREurope.
The first day of #ISPOREurope has been a huge success!
Our staff in attendance snapped this group photo as they were preparing to welcome clients to the evening reception.
Stop by and see us at booth C2-001 tomorrow!
We're just a few days away from #ISPOREurope! We're excited to attend this year's event with @corevitasdata, Thermo Fisher Scientific's latest acquisition that enhances our #RWD and #RWE solutions.
Meet us at booth C2-001, or schedule a chat with us. » https://t.co/XJPWgRSGzJ
Market approval does not guarantee commercial or clinical success. Regulatory considerations, #patientadherence and inflexible clinical workflows can hinder product uptake.
Our cutting-edge #implementationscience services can help address these barriers » https://t.co/14GWrCTzoq
Join our webinar on 7 November to explore the benefits and challenges of collecting #realworlddata (RWD) in continued and #earlyaccessprograms.
Register today! » https://t.co/d0CCEvwHsm
How will new European Union (EU) health technology assessment (#HTA) regulations commencing in 2025 impact your cell and gene therapy (CGT) submission?
We have your answers. » https://t.co/B1u6nQleop
Discover how #healtheconomic models play a pivotal role in product development, from early planning through analyses.
Register for this upcoming expert webinar to gain valuable insights. » https://t.co/Ltkd8id6YR
With OncoLocator data, insights into cancer treatments are endless.
Gaining a global understanding of standard of care. Evaluating #earlyphase assets and beyond. OncoLocator is more than data — it’s data smarter.
📈 https://t.co/FVvxNQrTje
#realworldevidence#realworlddata
Many #noveltherapies fail to get integrated into real-world clinical practice.
It's important to conduct a contextual analysis to understand the factors that could affect uptake, adoption and sustained use of a new therapy or health care technology. » https://t.co/14GWrCU7dY
Regulation (EU) 2021/2282 commences in January 2025 for #oncology and #ATMPs and will be fully implemented by 2030.
Discover how our value & access consultants can aid your European #marketaccess. » https://t.co/jKexAksIwD
Regulation (EU) 2021/2282 starts in January 2025 for #oncology and #ATMPs, with full implementation by 2030.
Learn how our value & access consultants can help you prepare for market access in Europe. » https://t.co/jKexAktgmb
Our iValue Suite™ helps create best-in-class value stories, global value dossiers, #HTA submissions, payer communication decks and objection handlers.
Contact us today to schedule a demo. » https://t.co/XKvU9e7ZdS
Donald Smith authored a white paper that defines the Pre-Approval Information Exchange (PIE) Act, compares it to the U.S. Food and Drug Administration (FDA) guidance, and outlines how implementation will support advancement of new therapies to market.
📥 https://t.co/kA4mItnA3C
What is driving the future of #realworldevidence?
Learn more from our blog, in which our thought leaders outline six key trends, including #realworlddata, #marketaccess, cross-industry collaboration initiatives and more. » https://t.co/OxhbZnCq08
We’re excited to announce the completion of the acquisition of @corevitasdata. CorEvitas provides insight to the life sciences industry that improves patient care and clinical outcomes, and together we will expand our clinical research services.
OncoLocator™ examines geographic differences in treatment across the most prevalent cancer indications in #womenshealth.
Would you like to explore more? Contact us for a free flat file sample and demo presentation. » https://t.co/A6VQvEvqcb
#niraparib#olaraparib#bevacizumab
Many #noveltherapies fail to get integrated into real-world clinical practice.
It's important to conduct a contextual analysis to understand the factors that could affect uptake, adoption and sustained use of a new therapy or health care technology. » https://t.co/14GWrCTzoq